A Phase 1 trial that is testing Modex's vaccine against the Epstein-Barr virus, a strong risk factor for MS, has dosed its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback